Also trades as: LIXTW (NASDAQ) · $vol 0M
LIXT NASDAQ
Lixte Biotechnology Holdings, Inc.
1W: +8.4%
1M: +2.4%
3M: +134.8%
YTD: +87.8%
1Y: +511.0%
3Y: +20.0%
5Y: -75.5%
$7.21
Last traded 2026-07-02 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
20 relationships20
As Filer
counterparties named
0
As Counterparty
mentioned by others
6
Rel. Types
2021-09-20
Earliest Filing
2026-03-10
Latest Filing
acquirer: 5
partner: 5
supplier: 4
target: 3
investor: 2
licensee: 1
Counterparties (Filed by LIXT)
20 relationshipsCompanies named in LIXT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Orbit Capital Inc. | — | acquirer | Seller in share exchange agreement | 2026-03-10 | View |
| Liora Technologies Europe Ltd. | — | target | Target company whose assets were acquired and shares exchanged | 2026-03-10 | View |
| Lixte Biotechnology Holdings, Inc. | LIXT | acquirer | PubCo acquiring shares in exchange for common stock | 2026-03-10 | View |
| Advanced Oncotherapy PLC | — | supplier | Seller of assets to Liora Technologies Europe Ltd. | 2026-03-10 | View |
| United Kingdom Research and Innovation | — | supplier | Landlord in lease agreement for Company Equipment | 2026-03-10 | View |
| Orbit Capital Inc. | — | investor | Shareholder exchanging Series C Preferred Stock for PubCo common stock and Liora shares | 2025-12-31 | View |
| Lixte Biotechnology Holdings, Inc. | LIXT | acquirer | PubCo acquiring Liora shares and issuing common stock to Orbit Capital | 2025-12-31 | View |
| Liora Technologies Europe Ltd. | — | target | Target company whose shares were acquired by PubCo and are being exchanged | 2025-12-31 | View |
| Orbit Capital Inc. | — | acquirer | Seller in the Share Exchange Agreement | 2025-11-25 | View |
| Liora Technologies Europe Ltd. | — | target | Company whose assets were acquired and shares exchanged | 2025-11-25 | View |
| Lixte Biotechnology Holdings, Inc. | LIXT | acquirer | PubCo acquiring the Company's shares | 2025-11-25 | View |
| Advanced Oncotherapy PLC | — | supplier | Seller of assets to Liora Technologies Europe Ltd. | 2025-11-25 | View |
| United Kingdom Research and Innovation | — | supplier | Landlord in the lease agreement for Company Equipment | 2025-11-25 | View |
| Medgenesis Global Inc. | — | investor | Original owner of Company shares sold to Orbit Capital Inc. | 2025-11-25 | View |
| WallachBeth Capital LLC | — | partner | Termination of At-the-Market Sales Agreement | 2025-03-11 | View |
| WallachBeth Capital LLC | — | partner | Agent for the At-The-Market Issuance Sales Agreement | 2025-01-06 | View |
| City of Hope National Medical Center | — | partner | Counterparty to terminated Clinical Research Support Agreement for Phase 1b clinical trial | 2024-07-12 | View |
| City of Hope Medical Foundation | — | partner | Counterparty to terminated Clinical Research Support Agreement for Phase 1b clinical trial | 2024-07-12 | View |
| Lixte Biotechnology, Inc. | LIXT | licensee | Exclusive licensee of jointly owned patent rights for LB-100 series compounds. | 2024-02-26 | View |
| WestPark Capital, Inc. | — | partner | Sales Agent for the issuance and sale of the Company's common stock. | 2021-09-20 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-31 | Regulation FD; Exhibits | View | |
| 2026-07-10 | Regulation FD; Exhibits | View | |
| 2026-07-02 | Material Agreement; Acquisition/Disposition; Unregistered Equity Sales; Officer/Director Change; Byl | Agreement Acquisition | View |
| 2026-06-18 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-06-16 | Material Agreement; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-06-04 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-06-01 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-04-17 | Officer/Director Change; Exhibits | View | |
| 2026-03-10 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-02-18 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-12-31 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-12-23 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-12-22 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Other Events | Agreement | View |
| 2025-12-11 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-11-25 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Unregi | Agreement Acquisition | View |
| 2025-09-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-09-04 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View | |
| 2025-08-19 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-14 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-21 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR